MTAMTech CORPORATION
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. Shortening New Drug Development Timelines and Saving R&D Expenses — MTAM/Screen/Trial (Matching Drugs to Cancer Patients): This service focuses on assisting CRO clients (pharmaceutical companies) by providing unique and innovative MTAM/HFA services, enhancing pharmacodynamic evaluation statistics and high-efficiency screening platforms, effectively shortening preclinical and clinical Phase I and Phase II timelines, saving approximately 80% of new drug development costs, while simultaneously tracking and analyzing preclinical trial data.
2. Screening Anticancer Drugs for Cancer Patients — MTAM/Select (Matching Patients to Cancer Drugs): This service focuses on rapid screening of anticancer drugs for cancer patient populations with an accuracy rate of over 90%, effectively enabling oncologists to promptly administer the most effective medication to each cancer patient, thereby improving treatment efficacy. Preventing the waste of national social security resources, reducing the financial burden of medical care on patients' families, and fighting for higher survival rates for cancer patients are precisely the original intentions behind the national promotion of personalized precision medicine.
2. Screening Anticancer Drugs for Cancer Patients — MTAM/Select (Matching Patients to Cancer Drugs): This service focuses on rapid screening of anticancer drugs for cancer patient populations with an accuracy rate of over 90%, effectively enabling oncologists to promptly administer the most effective medication to each cancer patient, thereby improving treatment efficacy. Preventing the waste of national social security resources, reducing the financial burden of medical care on patients' families, and fighting for higher survival rates for cancer patients are precisely the original intentions behind the national promotion of personalized precision medicine.
The content above was translated by Ai
Founded Year
2016
Unified Business No.
43935711
Status
Active
Number of Employees
0
Total Paid-in
Capital
18,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Anti-cancer drug screening solution for application in personalized medicine and drug development
The content above was translated by Ai
